Menopausal hormone therapy after breast cancer: The Stockholm randomized trial

Journal of the National Cancer Institute

Volumn 97, Issue 7, 2005, Pages 533-535

  von Schoultz, Eva ^a   Rutqvist, Lars E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; ESTRADIOL;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG FATALITY; DRUG SAFETY; EXPERIMENTAL DESIGN; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SWEDEN; AGED; BREAST TUMOR; CANCER STAGING; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; ESTROGEN THERAPY; HOT FLUSH; INCIDENCE; MENOPAUSE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RISK; SURVIVOR; TUMOR RECURRENCE;

AGED; BREAST NEOPLASMS; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HOT FLASHES; HUMANS; INCIDENCE; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; RESEARCH DESIGN; SURVIVORS; SWEDEN;

EID: 15944402092     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji071     Document Type: Article

References (10)

1. Holmberg L, Andersson H. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-5.
2. Söderqvist G, Isaksson E, von Schoultz B, Carlström K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123-8.
3. Cline JM, Söderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996;174:93-100.
4. Reid SE, Murthy MS, Kaufman M, Scanlon EF. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 1996;83:1037-46.
5. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16-23.
6. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002;100:1148-58.
7. Olsson HL, Ingvar C, Bladström A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97:1387-92.
8. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
9. The WHI steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
10. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002;359:1122-4.